Literature DB >> 6151904

Enhanced adenylate cyclase activity of turkey erythrocytes following treatment with beta-adrenergic receptor antagonists.

J R Peters, P Nambi, D R Sibley, R J Lefkowitz.   

Abstract

The turkey erythrocyte contains a beta 1-adrenergic receptor-linked adenylate cyclase system. We have examined the effects of pretreatment with receptor antagonists on adenylate cyclase activity and the individual components in the pathway of enzyme activation in this system. Isoproterenol-stimulated adenylate cyclase activity is increased by 30% (P less than 0.01) over control in membranes derived from cells preincubated with the antagonist propranolol. The effect is stereospecific and dose-related with a EC50 of 100 nM for the (-) isomer. The time course of effect is rapid being complete by 90 min. Non-receptor mediated stimulation of adenylate cyclase activity by manganese ion, forskolin and NaF is similarly enhanced following propranolol pretreatment. Sensitization of adenylate cyclase activity also occurs following pretreatment with a number of antagonists but is not seen after preincubation with pindolol or practolol. Quantitation of beta-adrenergic receptor (R) density using [125I]cyanopindolol indicates no difference between membranes derived from control and antagonist pretreated cells. Coupling of R with the guanine nucleotide regulatory protein (N) as assessed by high affinity agonist binding is unchanged following pretreatment. The efficacy of 5'-guanylylimidodiphosphate Gpp(NH)p in producing a shift of agonist binding curves associated with destabilization of high affinity H-R-N complexes, is also the same (EC50 = 0.2 microM) in membranes from control and antagonist treated cells. The isoproterenol stimulated rate of release of [3H]GDP from membranes preloaded with [3H]GTP as an index of formation of an active form of the N protein is similarly unaffected by antagonist preincubation. We conclude that the mechanism of the observed sensitization of turkey erythrocyte adenylate cyclase by beta-adrenergic antagonists is receptor mediated and likely involves facilitation of N interaction with the catalytic subunit of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6151904     DOI: 10.1016/0014-2999(84)90089-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Does treatment with beta-adrenoceptor antagonists in vivo alter human adenylate cyclase responsiveness in vitro?

Authors:  M C Michel; M Klüppel; T Philipp; O E Brodde
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

Review 2.  Metabolic engineering strategies to enable microbial utilization of C1 feedstocks.

Authors:  Wei Jiang; David Hernández Villamor; Huadong Peng; Jian Chen; Long Liu; Victoria Haritos; Rodrigo Ledesma-Amaro
Journal:  Nat Chem Biol       Date:  2021-07-26       Impact factor: 15.040

3.  Haemodynamic, metabolic, and lymphocyte beta 2-adrenoceptor changes following chronic beta-adrenoceptor antagonism.

Authors:  K Whyte; C R Jones; C A Howie; N Deighton; D J Sumner; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Inhibition of matrix metalloproteinase-9 secretion by dimethyl sulfoxide and cyclic adenosine monophosphate in human monocytes.

Authors:  Darcy R Denner; Maria Ld Udan-Johns; Michael R Nichols
Journal:  World J Biol Chem       Date:  2021-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.